vimarsana.com

Latest Breaking News On - Hematological malignancies - Page 7 : vimarsana.com

Oncternal Therapeutics Participating in Oppenheimer & Co s Virtual Fireside Chat: Discussion of ROR1 CAR T Cell Therapy in Hematological Malignancies and Solid Tumors

13.04.2023 - SAN DIEGO, April 13, 2023 (GLOBE NEWSWIRE) - Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that two key industry opinion leaders and .

Dr Jain on the Use of Haploidentical Donors in Myelofibrosis

Challenges in Standardizing Use of MRD Assessment in CLL

Although minimal residual disease (MRD) has emerged as a valuable prognostic marker across several hematological malignancies, its use in chronic lymphocytic leukemia (CLL) is mostly limited to clinical trials.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.